AI Article Synopsis
- Stage III non-small cell lung cancer is a serious type of lung cancer that can't be removed with surgery, so patients often get treated with a combination of chemotherapy, radiation, and a medicine called durvalumab for a year.
- This treatment has been shown to help about 49.2% of people survive for five years, but many still struggle and may not respond well.
- Experts suggest looking into new treatment options that focus on a process called ferroptosis, which might help improve results for those who resist the current treatments.
Article Abstract
Introduction: Stage III non-small cell lung cancer (NSCLC) is a composite of the regional spread of lung cancer with different levels of potential lymph node involvement and tumor size that often deem the stage at time of diagnosis to be unresectable and suitable for chemoradiation plus consolidation immunotherapy with durvalumab for 12 months. Chemoradiation plus durvalumab consolidation yielded a landmark 49.2% 5-year overall survival in unresectable NSCLC.
Areas Covered: Sub-optimal results lead us to focus on the mechanisms of resistance responsible for intractability in a significant proportion of cases that fail with chemoradiation and immunotherapy. In stage III NSCLC it is opportune to explore the accumulated evidence on ferroptosis resistance that can lead to cancer progression and metastasis. Strong data shows that three anti-ferroptosis pathways are principally involved in resistance to chemotherapy, radiation, and immunotherapy.
Expert Opinion: Because a large part of stage III NSCLCs is resistant to chemoradiation and durvalumab consolidation, a ferroptosis-based therapeutic approach, combined with standard-of-care therapy, can lead to improved clinical outcomes in patients diagnosed with stage III and possibly stage IV NSCLCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17476348.2023.2223985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!